Cybin Inc. Common Stock
HELP
NASDAQ·Healthcare·Medical - Pharmaceuticals·Mkt cap $757.4M
$12.22
▲ +3.82%
P/E
-2.97
Mkt Cap
$757.4M
52-Wk Range
$3.76–$14.35
52-Week Range
$3.76 - $14.35
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 106.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary deuteration technology enhancing compound efficacy
- Early-stage pipeline in emerging psychedelic medicine sector
- Clinical expertise in psychedelic-assisted therapy development
- Patent protection on novel psychedelic compounds
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Advancement of CYB003 and CYB004 through clinical trial stages
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+204.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying HELP right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 14, 2026
Reported EPS of -$0.91 vs -$0.84 consensus (-8.8% surprise).
EPS surprise · last 4Q
0 of 2 beats
Estimate
Actual
Q3 26
-8.8%
Q2 26
-14.3%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q4 26
Q1 27
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: TD Cowen · Aug 20, 2026
vs Industry
How HELP stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related